Figure S9 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

This is a In Vitro Study study.

Key Points

Combined treatment with XZ739 and S63845 significantly alters protein levels in CRPC models, and ensures a synergistic effect on tumor response.
The protein level changes in AR-V7-expressing CRPC were observed after just 24 hours of treatment, showing promising efficacy for this combination.
Observation from protein level changes underscores the potential of targeting Bcl-xL and Mcl-1 together in cancer therapies for CRPC.
These findings point to the need for further exploration of combined targeting strategies in therapeutic applications for prostate cancer.

Analysis reveals combined treatment with XZ739 and S63845 improves protein levels in CRPC models, suggesting enhanced efficacy.

Figure S9 depicts protein level changes after 24 hours of treatment with XZ739 alone or in combination with S63845.

No takes yet. Share an insight, caveat, or question.

Brim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share